Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00171990
Status:
COMPLETED
Last Update Posted:
2013-08-15
First Post:
2005-09-13
Brief Title:
Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes
Status:
COMPLETED
Status Verified Date:
2013-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase III multicenter randomized double-blind parallel-group study to compare the efficacy and safety of a two-day treatment with famciclovir 500 mg loading dose followed by 250 mg 12-hourly to standard five-day treatment with famciclovir 125 mg 12-hourly in patients with active recurrent genital herpes
This study is not recruiting patients in the United States
This study is not recruiting patients in the United States
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None